Evidence map›Paper›PMID 34129411›Full record

ReviewExpert review of proteomics2021

Mass Spectrometry Imaging of Fibroblasts: Promise and Challenge.

Peggi M Angel, Denys Rujchanarong, Sarah Pippin, Laura Spruill, Richard Drake

Open access · greenAbstract readReview
In one paragraph

Review in Expert review of proteomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Peggi M AngelBruker-MUSC Center of Excellence, Clinical Glycomics, Medical University of South Carolina, Charleston, SC, USA.
Denys RujchanarongBruker-MUSC Center of Excellence, Clinical Glycomics, Medical University of South Carolina, Charleston, SC, USA.
Sarah PippinBruker-MUSC Center of Excellence, Clinical Glycomics, Medical University of South Carolina, Charleston, SC, USA.
Laura SpruillDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA.
Richard DrakeBruker-MUSC Center of Excellence, Clinical Glycomics, Medical University of South Carolina, Charleston, SC, USA.
Medical University of South Carolina · USBruker (United States) · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2012 to 2020
$20.2M
Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Garth R Swanson · 2020 to 2026
$8.8M
Sociobiological Responses to Stress in Prostate Cancer SurvivorsU54MD010706 · NIMHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DRAKE, RICHARD R. · 2016 to 2020
$8.0M
MUSC Minority Student Development ProgramR25GM072643 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE, RINKER, JENNIFER ANNE · 2005 to 2023
$5.8M
Deciphering the Glycan Code in Human Alzheimer’s Disease BrainR01AG078702 · NIA · UNIVERSITY OF KENTUCKY · PI Peggi M Angel, Sean Curtis Bendall · 2022 to 2026
$3.8M
MUSC Post-Baccalaureate Research Education ProgramR25GM113278 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DELEON-PENNELL, KRISTINE Y, PENROD-MARTIN, RACHEL · 2015 to 2024
$2.7M
Collagen Sequence Variants in Racial Disparities of Breast CancerR01CA253460 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2020 to 2024
$2.6M
Enzymatic Tools for 2D Tissue Localized and Deeper Proteomic Sequencing of Cancer Stromal ProteinsR21CA240148 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2019 to 2020
$480k
NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA253460NCI NIH HHS R21 CA240148NIA NIH HHS R01 AG078702NIDDK NIH HHS P30 DK123704NIGMS NIH HHS P20 GM103542NIGMS NIH HHS R25 GM072643NIGMS NIH HHS R25 GM113278NIMHD NIH HHS U54 MD010706
6 · The paper itself

Abstract

introductionFibroblasts maintain tissue and organ homeostasis through output of extracellular matrix that affects nearby cell signaling within the stroma. Altered fibroblast signaling contributes to many disease states and extracellular matrix secreted by fibroblasts has been used to stratify patient by outcome, recurrence, and therapeutic resistance. Recent advances in imaging mass spectrometry allow access to single cell fibroblasts and their ECM niche within clinically relevant tissue samples. AREAS COVERED: We review biological and technical challenges as well as new solutions to proteomic access of fibroblast expression within the complex tissue microenvironment. Review topics cover conventional proteomic methods for single fibroblast analysis and current approaches to accessing single fibroblast proteomes by imaging mass spectrometry approaches. Strategies to target and evaluate the single cell stroma proteome on the basis of cell signaling are presented. EXPERT OPINION: The promise of defining proteomic signatures from fibroblasts and their extracellular matrix niches is the discovery of new disease markers and the ability to refine therapeutic treatments. Several imaging mass spectrometry approaches exist to define the fibroblast in the setting of pathological changes from clinically acquired samples. Continued technology advances are needed to access and understand the stromal proteome and apply testing to the clinic.

Indexed as

FibroblastsProteomicsExtracellular MatrixHumansMass SpectrometryProteomeProteomeextracellular matrixFibroblastimaging mass spectrometryimaging proteomicsmass spectrometryproteomicsstromatissue

Identifiers

PMID34129411
PMCPMC8717608
OpenAlexW3170270978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.